Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor

DOV 216,303 [(±)‐1‐(3,4‐dichlorophenyl)‐3‐azabicyclo‐[3.1.0]hexane hydrochloride] is the prototype of a class of compounds referred to as “triple” reuptake inhibitors. Such compounds inhibit the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), the three neurotransmitters most cl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CNS Drug Rev
Main Authors: Skolnick, Phil, Krieter, Philip, Tizzano, Joseph, Basile, Anthony, Popik, Piotr, Czobor, Pal, Lippa, Arnold
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Inc 2006
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494125/
https://ncbi.nlm.nih.gov/pubmed/16958986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2006.00123.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados